US equities |
TSLA $391.62 ▲+5.21% MU $903.70 ▲+2.98% META $630.56 ▼-1.88% NVDA $216.00 ▲+2.39% AAPL $343.91 ▼-1.10% SPCX $146.90 ▼-0.40% MSFT $532.60 ▲+1.54% AMD $531.28 ▲+2.80%
FinancialContent

Certara, Inc. - Common Stock (NQ:CERT)

10.61 +0.28 (+2.71%)
Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Certara, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development
From Altasciences
Via Business Wire
News headline image
Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat
From Certara
Via GlobeNewswire
News headline image
Certara to Report First Quarter 2026 Financial Results on May 11th, 2026
From Certara
Via GlobeNewswire
News headline image
Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib
Biosimulation results highlight how model-informed approaches for drug development and regulatory decision-making save time and money. 
From Certara
Via GlobeNewswire
Certara Inc (NASDAQ:CERT) Reports Mixed Q4 2025 Results and Cautious 2026 Outlook ↗
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
News headline image
Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance
From Certara
Via GlobeNewswire
News headline image
Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025
From Certara
Via GlobeNewswire
News headline image
Certara’s Volatility: From a 23% Earnings Plunge to a $3 Million Institutional Vote of Confidence
The biosimulation market was sent into a tailspin in the closing months of 2025 as Certara (Nasdaq:CERT), a global leader in model-informed drug development, saw its market valuation crater by 23%. The... 
Via MarketMinute
Topics Earnings
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Certara Stock Fell 23% After Earnings and This Fund Bought Up $3 Million Anyway ↗
Certara provides biosimulation software and regulatory solutions to global biopharma clients, supporting drug development and approvals. 
Via The Motley Fool
News headline image
Healthcare AI Exits Pilot Phase, Enters Production Deployment
Issued on behalf of VentriPoint Diagnostics Ltd. 
From Equity Insider
Via GlobeNewswire
News headline image
Certara Appoints Jon Resnick as Chief Executive Officer
From Certara
Via GlobeNewswire
News headline image
ArrowMark Slashes Alight Position Amid Growing Questions About Its Recurring-Revenue Strategy ↗
ArrowMark’s sharp reduction in its Alight stake comes at a moment when the market is questioning whether the company can turn its consulting-heavy work into steadier recurring revenue, and that tension... 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Next Wave Of AI Winners? Investors Shift Focus Beyond Nvidia ↗
Goldman Sachs says investors are shifting toward companies quietly using AI to cut costs and drive productivity-led growth. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Certara Reports Third Quarter 2025 Financial Results
Updates Full Year 2025 Financial Guidance 
From Certara
Via GlobeNewswire
News headline image
Certara Automates Scientific Workflows with Phoenix® Cloud
New cloud capabilities cut time to create Tables, Figures, and Listings by 50% 
From Certara
Via GlobeNewswire
News headline image
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
News headline image
Certara Expands Biosimulation Market with AI-Driven QSP Platform
Certara IQ™ integrates AI and biosimulation to accelerate R&D productivity, reduce risk, and deepen understanding of novel and complex therapies 
From Certara
Via GlobeNewswire
News headline image
Certara Scientists are Among the Topmost Cited Biopharma Researchers
Certara celebrates its 200 published papers and 11 scientists on Stanford/Elsevier top 2% cited researchers list in 2025 
From Certara
Via GlobeNewswire
News headline image
Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025
From Certara
Via GlobeNewswire
News headline image
Beyond The Numbers: 4 Analysts Discuss Certara Stock ↗
 
Via Benzinga
News headline image
RH Posts Downbeat Results, Joins Frequency Electronics, Tronox And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions Faster
Solution delivers a 50% reduction in time spent drafting mapping specifications, according to internal measurements 
From Certara
Via GlobeNewswire
News headline image
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
News headline image
Certara (CERT) Q2 Revenue Jumps 12% ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Certara Reports Second Quarter 2025 Financial Results
Reiterates Full Year 2025 Financial Guidance 
From Certara
Via GlobeNewswire
News headline image
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling
From Certara
Via GlobeNewswire
News headline image
Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform
Strengthening technology innovation and leadership of the Certara AI/ML-enabled biosimulation platform used to speed time to market in drug discovery and development 
From Certara
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >